Hemofarm’s core activity is production of high-quality, safe, effective and available generic pharmaceutical products by applying high-end technologies. Hemofarm manufactures medicinal products of all pharmaco-therapeutic groups and forms, from simplest to most complex ones:
it sells products of 12 (out of 14) pharmaco-therapeutic groups according to the ATC classification,
portfolio contains 192 products by INN, with 38...
Hemofarm’s core activity is production of high-quality, safe, effective and available generic pharmaceutical products by applying high-end technologies. Hemofarm manufactures medicinal products of all pharmaco-therapeutic groups and forms, from simplest to most complex ones:
it sells products of 12 (out of 14) pharmaco-therapeutic groups according to the ATC classification,
portfolio contains 192 products by INN, with 388 forms and dosages,
portfolio is focused on most important pharmaco-therapeutic groups, such as products for cardiovascular diseases, antibiotics and neuropsychiatric products,
over-the-counter (OTC) products have a leading position in the Serbian pharmaceutical market, with a share exceeding 13%,
constant improvement of portfolio with new generations of medicines,
development of new segments, primarily oncology.
Hemofarm is a leader in the local market of pharmaceuticals, competing against 300 manufacturers and distributors1, with a share of 34% in goods, i.e. 17.5% in value.
Business operations within STADA Group open additional possibilities for sales of products to very demanding EU markets. The new strategic portfolio approach has been ‘tailor-made’ to suit the requirements of each region.it sells products of 12 (out of 14) pharmaco-therapeutic groups according to the ATC classification,
portfolio contains 192 products by INN, with 388 forms and dosages,
portfolio is focused on most important pharmaco-therapeutic groups, such as products for cardiovascular diseases, antibiotics and neuropsychiatric products,
over-the-counter (OTC) products have a leading position in the Serbian pharmaceutical market, with a share exceeding 13%,
constant improvement of portfolio with new generations of medicines,
development of new segments, primarily oncology.
Hemofarm is a leader in the local market of pharmaceuticals, competing against 300 manufacturers and distributors1, with a share of 34% in goods, i.e. 17.5% in value.
Business operations within STADA Group open additional possibilities for sales of products to very demanding EU markets. The new strategic portfolio approach has been ‘tailor-made’ to suit the requirements of each region.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.